U.S. FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of relapsed/refractory diffuse large B-cell...

OnCusp Therapeutics receives FDA Fast Track Designation for CUSP06 for the treatment of platinum-resistant ovarian...

DAAN Biotherapeutics signs antibody exclusive licensing agreement with LigaChem Biosciences for ADC therapeutic development

IDEAYA announces further Gilead sciences clinical study collaboration evaluating combination of Trodelvy and IDE397 in...

Ellipses In-Licences first in class novel Immuno-oncology agent with potential as a next generation checkpoint...

Pfizer and Astellas’ PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA (pembrolizumab) shows long-term efficacy in first-line treatment...